At the news
? NEUTRALIMPACT 3/10 8-K filed Feb 24, 2026 at 17:14 ET
Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer effective February 18, 2026. Huston receives an annual base salary of $540,000 and an inducement grant of 220,000 restricted stock units, with vesting over four years. The appointment reflects a strategic leadership addition in the biotech firm's financial management.
- Thad Huston appointed CFO effective February 18, 2026
- Annual base salary of $540,000 with 40% target bonus
- Inducement grant of 220,000 RSUs under 2025 Inducement Plan
- RSUs vest over four years: 25% on February 15, 2027, then quarterly
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access